Chemocentryx Stock Executives

CCXI -  USA Stock  

USD 15.32  0.21  1.39%

Chemocentryx employes about 133 people. The company is managed by 15 executives with total tenure of roughly 103 years, averaging almost 6.0 years of service per executive having 8.87 employees per reported executive. Examination of Chemocentryx management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Chemocentryx future performance.
Continue to Trending Equities.

Search Insiders 

 
Refresh
  Thomas Schall  Chairman
Founder, Chairman, CEO and Pres
  Israel Charo  President
Senior Vice President - Research
  Jan Hillson  President
Senior Vice President - Drug Development

Chemocentryx Return on Sales

(0.87)Share

Chemocentryx Management Team Effectiveness

Chemocentryx has return on total asset (ROA) of (11.2) % which means that it has lost $11.2 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (30.1) %, meaning that it created substantial loss on money invested by shareholders. Chemocentryx management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -24.01. The current Return on Average Assets is estimated to decrease to -0.13. Chemocentryx Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 77.33 Million. The current Revenue to Assets is estimated to increase to 0.18, while Return on Average Assets are projected to decrease to (0.13) .

Chemocentryx Quarterly Total Assets

499.11 MillionShare
The current Issuance Purchase of Equity Shares is estimated to increase to about 384.1 M, while Weighted Average Shares is projected to decrease to roughly 57.7 M.

Chemocentryx Workforce Comparison

Chemocentryx is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 390. Chemocentryx totals roughly 133 in number of employees claiming about 34% of stocks in Biotechnology industry.

Chemocentryx Profit Margins

The company has Profit Margin (PM) of (91.54) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (90.1) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.9.

Chemocentryx Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Chemocentryx insiders, such as employees or executives, is commonly permitted as long as it does not rely on Chemocentryx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Chemocentryx insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Chemocentryx Benchmark Summation

Chemocentryx Notable Stakeholders

A Chemocentryx stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Chemocentryx often face trade-offs trying to please all of them. Chemocentryx's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Chemocentryx's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Thomas Schall - Founder, Chairman, CEO and PresProfile
Israel Charo - Senior Vice President - ResearchProfile
Jan Hillson - Senior Vice President - Drug DevelopmentProfile
Petrus Bekker - Senior Vice President - Clinical and Medical AffairsProfile
William Fairey - COO, Executive Vice PresidentProfile
Rajinder Singh - Senior Vice President - ResearchProfile
Susan Kanaya - CFO, Sr. VP of Fin. and SecretaryProfile
Geoffrey Parker - Independent DirectorProfile
Joseph Feczko - Independent DirectorProfile
Thomas Edwards - Independent DirectorProfile
James Tyree - Independent DirectorProfile
Henry McKinnell - DirectorProfile
Roger Lucas - Lead Independent DirectorProfile
Rita Jain - Independent DirectorProfile
Markus Cappel - Chief Bus. Officer and TreasurerProfile

About Chemocentryx Management Performance

The success or failure of an entity such as Chemocentryx often depends on how effective the management is. Chemocentryx management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Chemocentryx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Chemocentryx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Return on Investment(22.26) (24.01) 
Return on Average Assets(0.12) (0.13) 
Return on Average Equity(0.17) (0.19) 
Return on Invested Capital(0.16) (0.18) 
Return on Sales(0.81) (0.87) 
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California. Chemocentryx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.
The data published in Chemocentryx's official financial statements usually reflect Chemocentryx's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Chemocentryx. For example, before you start analyzing numbers published by Chemocentryx accountants, it's critical to develop an understanding of what Chemocentryx's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Chemocentryx's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Chemocentryx's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Chemocentryx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Chemocentryx. Please utilize our Beneish M Score to check the likelihood of Chemocentryx's management to manipulate its earnings.

Chemocentryx Workforce Analysis

Traditionally, organizations such as Chemocentryx use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Chemocentryx within its industry.

Chemocentryx Manpower Efficiency

Return on Chemocentryx Manpower

Revenue Per Employee450.8 K
Revenue Per Executive4.6 M
Net Loss Per Employee447.8 K
Net Loss Per Executive4.2 M
Working Capital Per Employee500.3 K
Working Capital Per Executive4.4 M
Today, most investors in Chemocentryx Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Chemocentryx's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Chemocentryx per employee as a starting point in their analysis.

Per Employee

Chemocentryx Per Employee Growth Over Time

Net Income Per Employee

(447,842)Share
Chemocentryx Net Income Per Employee is most likely to decrease significantly in the upcoming years. The last year's value of Net Income Per Employee was reported at (415,073)

Revenue Per Employee

450,822Share
Chemocentryx Revenue Per Employee is most likely to increase significantly in the upcoming years. The last year's value of Revenue Per Employee was reported at 486,569
Continue to Trending Equities. Note that the Chemocentryx information on this page should be used as a complementary analysis to other Chemocentryx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Chemocentryx Stock analysis

When running Chemocentryx price analysis, check to measure Chemocentryx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemocentryx is operating at the current time. Most of Chemocentryx's value examination focuses on studying past and present price action to predict the probability of Chemocentryx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chemocentryx's price. Additionally, you may evaluate how the addition of Chemocentryx to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
The market value of Chemocentryx is measured differently than its book value, which is the value of Chemocentryx that is recorded on the company's balance sheet. Investors also form their own opinion of Chemocentryx's value that differs from its market value or its book value, called intrinsic value, which is Chemocentryx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemocentryx's market value can be influenced by many factors that don't directly affect Chemocentryx underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemocentryx's value and its price as these two are different measures arrived at by different means. Investors typically determine Chemocentryx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemocentryx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.